Efficacy of bethanechol chloride in the treatment of radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis.
Radiother Oncol
; 186: 109715, 2023 09.
Article
em En
| MEDLINE
| ID: mdl-37207874
ABSTRACT
BACKGROUND AND PORPUSE Salivary glands sustain collateral damage following radiotherapy (RT) to treat cancers of the head and neck, leading to complications, including xerostomia and hyposalivation. This systematic review (SR) with meta-analysis was performed to determine the effectiveness of bethanechol chloride in preventing salivary gland dysfunction in this context. MATERIALS AND METHODS:
Medline/Pubmed, Embase, Scopus, LILACS via Portal Regional BVS and Web of Science were searched electronically in accordance with the Cochrane manual and reported PRISMA guidelines.RESULTS:
170 patients from three studies were included. Results from the meta-analysis suggest that bethanechol chloride is associated with increases in whole stimulating saliva (WSS) after RT (Std. MD 0.66, 95% CI 0.28 to 1.03, P < 0.001); whole resting saliva (WRS) during RT (Std. MD 0.4, 95% CI 0.04 to 0.76, P = 0.03); and WRS after RT (Std. MD 0.45, 95% CI 0.04 to 0.86, P = 0.03).CONCLUSION:
The present study suggests that bethanechol chloride therapy may be effective in patients with xerostomia and hyposalivation.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Lesões por Radiação
/
Xerostomia
/
Betanecol
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article